Generalized Pustular Psoriasis (GPP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Generalized Pustular Psoriasis (GPP) Market Outlook

Thelansis’s “Generalized Pustular Psoriasis (GPP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Generalized Pustular Psoriasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Generalized Pustular Psoriasis (GPP) Overview

Generalized pustular psoriasis is an uncommon and severe variant of psoriasis, marked by sudden, painful outbreaks of pus-filled blisters covering extensive body areas. It can also bring general symptoms like fever, headaches, extreme fatigue, and skin-burning sensations. Distinguishing it from the more typical plaque psoriasis is essential. Several factors can trigger or worsen generalized pustular psoriasis, including:

1. Infections: Viral or bacterial infections often exacerbate the condition.
2. Medications: Corticosteroids are a significant trigger, but other drugs like ciclosporin, terbinafine, and others have been implicated.
3. Psychological Stress: Stress can lead to deterioration in some individuals.
4. Hypocalcemia: Low calcium levels, either from the disease or other causes like hypoparathyroidism, can activate the condition.
5. Pregnancy: Pregnancy is a recognized risk factor.

In certain populations, genetic mutations in IL36RN have been linked to familial and sporadic cases of generalized pustular psoriasis, with specific mutations varying among populations. Diagnostic laboratory tests include elevated erythrocyte sedimentation rate, C-reactive protein levels, lymphopenia followed by leukocytosis, low plasma albumin, zinc, calcium, and abnormal lipid profiles. The disease may be mistaken for a systemic infection due to fever and elevated inflammatory markers during acute phases, potentially leading to incorrect treatment decisions. Without effective treatment, the acute phase can be life-threatening. Prognosis is generally better when there is a clear trigger, such as pregnancy-related generalized pustular psoriasis. However, cases stemming from acrodermatitis continua of Hallopeau tend to have a worse outlook. Treatment for generalized pustular psoriasis involves various approaches - Conservative Treatment includes - Encouraging adequate fluid and protein intake, Monitoring fluid balance, Addressing any concurrent infections with antibiotics, terminating the pregnancy if maternal life is at risk, and preventing hypothermia. Topical Treatment includes- Applying gentle emollients and Using diluted corticosteroids. Systemic Treatment (in order of preference)- First line- Acitretin (not recommended during pregnancy) at a dose of 1 mg/kg/day, Ciclosporin at 3.5 to 5 mg/kg/day, Methotrexate at 0.2 to 0.4 mg/kg/day. Second line- Infliximab, Adalimumab, Etanercept, Prednisolone (only in specific conditions or complications). Third line - Anakinra.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: